Lornoxicam (Trade name: “Xefo”) belongs to a non-steroidal anti-inflammatory drug. As a kind of oxicam class drug, it has analgesic, anti-inflammatory and antipyretic properties. It can be used for the treatment of various type of acute mild to moderate pain which results from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica and rheumatic diseases. Lornoxicam is capable of potently inhibiting the prostaglandin biosynthesis process, making it have highly pronounced efficacy. The exact mechanism of Lornoxicam is not exactly understood. However, it is indicated that Lornoxicam can inhibit the prostaglandin and thromboxane synthesis by inhibiting both COX-1 and COX-2, leading to reduction of inflammation, pain, fever, and swelling.
https://www.drugbank.ca/drugs/DB06725
https://en.wikipedia.org/wiki/Lornoxicam
Lornoxicam is a COX inhibitor and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic properties. It inhibits production of thromboxane B2 (TXB2; ) from arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607) in HEL human erythroleukemic cells (IC50 = 3 nM), which endogenously express COX-1, as well as inhibits LPS-induced formation of prostaglandin F1α (PGF1α; ) from arachidonic acid in Mono-Mac-6 cells (IC50 = 8 nM), which endogenously express COX-2. Lornoxicam reduces LPS-induced production of nitric oxide and IL-6 in cell-based assays with IC50 values of 65 and 54 μM, respectively. It reduces carrageenan-induced paw edema in rats when administered intravenously at doses ranging from 0.1 to 9 mg/kg. Formulations containing lornoxicam have been used in the management of postoperative pain.
Lornoxicam is a nonselective NSAID for oral and intravenous administration. It has been available for human use since two decades and there is a growing body of evidence supporting its efficacy and tolerability for management of acute pain.
Xefo, a member of the oxicam family of nonsteroidal antiinflammatory agents, was launched in Denmark for mild to moderate pain and inflammation. A seven step synthesis, beginning with 2,5-dichlorothiophene, provides access to this compound. It inhibits prostaglandin synthesis at the level of cyclooxygenase (Cox1 :Cox2 = 0.6) but does not inhibit 5-lipoxygenase. Xefo did not increase serum levels of pepsinogen I (an indicator of gastric mucosal status) and readily penetrates perivascular interstitial spaces including synovial fluid. It is as effective as morphine, meperidine and tramadol in relieving post operative pain and as efficient as other NSAlDs in relieving the symptoms of osteoarthritis and rheumatoid arthritis. It is 100 times more potent than Tenoxicam in inhibiting PGD2 and more active than indomethacin (6x) or piroxicam (10x) in preventing arachadonic acid influenced lethality in mice. Xefo has inhibitor effects on spinal nocicceptive processing presumably via release of endogenous opiods and evidence suggests it is good for migraine.
Nycomed Amersham (Norway)
For the treatment of acute mild to moderate pain, as well as pain and inflammation of the joints caused by certain types of rheumatic diseases.
keratolytic, antiacne, antineoplastic
Cyclooxygenase inhibitor; structurally similar to tenoxicam. Anti-inflammatory; analgesic
Lornoxicam belongs to the oxicam class. It has anti-inflammatory and antipyretic properties. Lornoxicam prevents the synthesis of prostaglandin (PG) by inhibiting cyclo-oxygenase. It is used to relieve various types of symptoms associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute sciatica and low back pain.Lornoxicam is approved for use in Japan.
Lornoxicam has been used as a drug in melanin binding study with cassette dosing and rapid equilibrium dialysis inserts. Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug.
Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) that is used as a painkiller (analgesic). A high level of pain relief is experienced by about 45% of those with moderate to severe postoperative dental pain after a single dose of lornoxicam 8 mg, compared to about 10% with placebo. This is comparable to the proportion experiencing the same level of pain relief with ibuprofen 200 to 400 mg. Adverse events were generally mild and did not differ from placebo in these singe dose studies. There were insufficient data to assess duration of action, but it is likely to be similar to ibuprofen 200 mg.
ChEBI: A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 6-chloro-4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for th
treatment of pain, primarily resulting from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica and other inflammations.
studies on intact human cells showed that lornoxicam intensively inhibit cox-1 and cox-2 with the lowest ic50 among a large panel of nsaids tested. similar findings were obtained in the whole blood for cox-1/-2. in addition lornoxicam suppressed no formation in a dose-dependently manner with an ic50 of 65 μm. [2]
in vivo studies found that lornoxicam was as effective as comparative nsaids and that 8 mg lornoxicam was more effective than 10 mg morphine as a pain-reliever after oral surgery. orally administration of lornoxicam at 16-24 mg daily was more effective than tramadol at 300 mg daily in pain-alleviating after knee surgery. compared to naproxen, lornoxicam showed higher therapeutic potency and lower gastrointestinal toxicity. this was probably due to the short half-life of lornoxicam as compared to the other oxicams. [3]
a potent cox-1 and cox-2 inhibitor with ic50 values of 5 nm and 8 nm, respectively.
[1]balfour ja, fitton a and barradell lb. lornoxicam, a review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. drugs. 1996 apr; 51(4): 639-57.
[2]berg j, fellier h, christoph t, grarup j and stimmeder d. the analgesic nsaid lornoxicam inhibits cyclooxygenase (cox)-1/-2, inducible nitric oxide synthase (inos), and the formation of interleukin (il)-6 in vitro. inflamm res. 1999 jul; 48(7): 369-79.
[3]radhofer-welte s and rabasseda x. lornoxicam, a new potent nsaid with an improved tolerability profile. drugs today (barc). 2000 jan; 36(1): 55-76.
[4]sharma a, pingle a, and baliga vp. lornoxicam efficacy in acute pain (leap) trial. j indian med assoc. 2008 dec; 106(12): 811-3.
